2020
Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent? CardioVascular And Interventional Radiology 2020, 43: 721-731. PMID: 32140840, DOI: 10.1007/s00270-020-02434-4.Peer-Reviewed Original ResearchConceptsC hepatocellular carcinomaChild-Pugh AAdvanced hepatocellular carcinomaOverall survivalHepatocellular carcinomaBCLC stage C hepatocellular carcinomaEastern Cooperative Oncology Group scoreBCLC-C hepatocellular carcinomasMultivariable Cox regression analysisChild-Pugh scoreMedian overall survivalChild-Pugh classKaplan-Meier methodCox regression analysisYttrium-90 RadioembolizationLog-rank testCautious patient selectionSignificant independent predictorsChild-PughHCV infectionResultsMean ageY90 radioembolizationAdditional malignanciesConsecutive patientsIndependent predictorsEffect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survival
2019
Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database
Byrne RM, Gilbert EW, Dewey EN, Herzig DO, Lu KC, Billingsley KG, Deveney KE, Tsikitis VL. Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database. Journal Of Surgical Research 2019, 238: 198-206. PMID: 30772678, DOI: 10.1016/j.jss.2019.01.039.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAppendiceal NeoplasmsChemotherapy, AdjuvantChemotherapy, Cancer, Regional PerfusionCytoreduction Surgical ProceduresDatabases, FactualFemaleHumansHyperthermia, InducedKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesSex FactorsTreatment OutcomeUnited StatesConceptsPerioperative intraperitoneal chemotherapyAppendiceal cancerCytoreductive surgeryIntraperitoneal chemotherapyTreatment modalitiesNational Cancer Database dataMultivariate logistic regression analysisNational Cancer DatabasePatterns of careLow-grade tumorsNon-Hispanic ethnicityLogistic regression analysisMucinous malignanciesSystemic chemotherapyMultimodality treatmentClinical factorsImproved survivalPatient selectionMale sexKaplan-MeierPatient cohortCancer DatabaseWhite raceTreatment groupsChemotherapy
2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas
Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals Of Surgical Oncology 2018, 25: 920-927. PMID: 29388122, DOI: 10.1245/s10434-018-6346-4.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasHigh-risk soft tissue sarcomasPhase II studyII studyPreoperative radiationTissue sarcomasHigh-grade soft tissue sarcomasHigh-risk STS patientsDistant disease-free survivalM2/dayExtensive institutional experienceLocal-regional failureDisease-free survivalRetrospective chart reviewDose-intense chemotherapyFavorable clinical outcomePercent of tumorsGy of radiationPostoperative cyclesTrimodality therapyPreoperative therapyWound complicationsChart reviewOverall survivalPathologic response
2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2015
Malignancy does not dictate the hypercoagulable state following liver resection
Gordon N, Riha G, Billingsley K, Schreiber M. Malignancy does not dictate the hypercoagulable state following liver resection. The American Journal Of Surgery 2015, 209: 870-874. PMID: 25805455, DOI: 10.1016/j.amjsurg.2014.12.022.Peer-Reviewed Original ResearchConceptsRelative hypercoagulable stateLiver resectionHypercoagulable stateMalignant diseaseTEG valuesMalignancy statusCause of hypercoagulabilityPostoperative coagulopathyCoagulation profileRetrospective reviewResectionNormal rangePatientsDiseaseSignificant differencesMalignancyMedian valueR timeStatusCoagulopathyHypercoagulabilityGroup
2014
Chemoradiotherapy with a Radiation Boost for Anal Cancer Decreases the Risk for Salvage Abdominoperineal Resection: Analysis From the National Cancer Data Base
Geltzeiler C, Nabavizadeh N, Kim J, Lu K, Billingsley K, Thomas C, Herzig D, Tsikitis V. Chemoradiotherapy with a Radiation Boost for Anal Cancer Decreases the Risk for Salvage Abdominoperineal Resection: Analysis From the National Cancer Data Base. Annals Of Surgical Oncology 2014, 21: 3616-3620. PMID: 24943237, DOI: 10.1245/s10434-014-3849-5.Peer-Reviewed Original ResearchThe international normalized ratio overestimates coagulopathy in patients after major hepatectomy
Louis S, Barton J, Riha G, Orloff S, Sheppard B, Pommier R, Underwood S, Differding J, Schreiber M, Billingsley K. The international normalized ratio overestimates coagulopathy in patients after major hepatectomy. The American Journal Of Surgery 2014, 207: 723-727. PMID: 24791634, DOI: 10.1016/j.amjsurg.2013.12.021.Peer-Reviewed Original ResearchConceptsInternational normalized ratioMajor hepatectomyNormalized ratioPatient populationElevated international normalized ratioUse of thrombelastographyPostoperative day 1Postoperative time pointsHypercoagulable statePreoperative valuesDecreased incidenceProcoagulant factorsTEG measurementsCoagulation factorsDay 1ThrombelastographyHepatectomyFactor VIIISubsequent normalizationPatientsTime pointsHypocoagulabilityTherapyProtein C.
2013
Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy
Gur I, Diggs B, Wagner J, Vaccaro G, Lopez C, Sheppard B, Orloff S, Billingsley K. Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy. Journal Of Gastrointestinal Surgery 2013, 17: 2133-2142. PMID: 24091909, DOI: 10.1007/s11605-013-2295-1.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPreoperative chemotherapyPerioperative chemotherapyOverall survivalLiver metastasesAdvanced ageResectable colorectal liver metastasesPreoperative portal vein embolizationShorter disease-free intervalAcademic oncology centerOutcomes Following ResectionThirty-day mortalityDisease-free intervalHigh-risk patientsPortal vein embolizationSubset of patientsPoor overall survivalLiver recurrenceSynchronous diseaseEleven patientsPostoperative complicationsRepeat resectionLiver resectionVein embolizationRetrospective reviewCoagulopathy after a liver resection: is it over diagnosed and over treated?
Barton J, Riha G, Differding J, Underwood S, Curren J, Sheppard B, Pommier R, Orloff S, Schreiber M, Billingsley K. Coagulopathy after a liver resection: is it over diagnosed and over treated? Hepato Pancreato Biliary 2013, 15: 865-871. PMID: 23458574, PMCID: PMC4503284, DOI: 10.1111/hpb.12051.Peer-Reviewed Original ResearchConceptsProthrombin time-international normalized ratioPost-operative time pointsLiver resectionPost-operative day 1Initiation of thromboprophylaxisLiver resection patientsNormal coagulation functionTime pointsPT-INR valuesTime of onsetProphylactic anticoagulationElective hepatectomyResection patientsPlasma transfusionHypercoagulable stateAnesthetic techniqueCoagulation functionNormalized ratioPlasma therapyPringle manoeuverRelative hypercoagulabilityFunctional assessmentDay 1ResectionThrombelastography
2011
Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy
Massimino K, Kolbeck K, Enestvedt C, Orloff S, Billingsley K. Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. Hepato Pancreato Biliary 2011, 14: 14-19. PMID: 22151446, PMCID: PMC3252986, DOI: 10.1111/j.1477-2574.2011.00402.x.Peer-Reviewed Original ResearchConceptsRight portal vein embolizationPortal vein embolizationFuture liver remnantShort-term outcomesFLR volumeVein embolizationPreoperative right portal vein embolizationMajor right hepatectomyPost-embolization complicationsPostoperative liver failureRecords of patientsResults of embolizationDegree of hypertrophyHypertrophy rateRight hepatectomyLiver resectionMost complicationsOperative complicationsOperative resectionPatient demographicsComplication rateLiver failureLiver insufficiencyOperative outcomesLiver remnantS0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3Predicting malignant intraductal papillary mucinous neoplasm: a single-center review
Cone M, Rea J, Diggs B, Douthit M, Billingsley K, Sheppard B. Predicting malignant intraductal papillary mucinous neoplasm: a single-center review. The American Journal Of Surgery 2011, 201: 575-579. PMID: 21545902, DOI: 10.1016/j.amjsurg.2011.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryDiagnosis, DifferentialEndosonographyFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival RateTime FactorsTomography, X-Ray ComputedUnited StatesConceptsIntraductal papillary mucinous neoplasmInternational consensus guidelinesMalignant intraductal papillary mucinous neoplasmPapillary mucinous neoplasmConsensus guidelinesMucinous neoplasmsInvasive cancerMain duct intraductal papillary mucinous neoplasmPancreatic intraductal papillary mucinous neoplasmsPercent of patientsSingle-center reviewHigh-grade dysplasiaMayo criteriaWorse survivalPatient groupFemale sexSingle institutionMayo ClinicLower riskPatientsMultivariate analysisCancerResectionMain ductNeoplasmsOutcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases
Hammill C, Billingsley K, Cassera M, Wolf R, Ujiki M, Hansen P. Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases. Annals Of Surgical Oncology 2011, 18: 1947-1954. PMID: 21399885, DOI: 10.1245/s10434-010-1535-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedCatheter AblationCohort StudiesColorectal NeoplasmsCombined Modality TherapyFemaleFollow-Up StudiesHumansLaparoscopyLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPreoperative CareProspective StudiesRetrospective StudiesSurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsColorectal liver metastasesLaparoscopic radiofrequency ablationResectable colorectal liver metastasesRadiofrequency ablationResectable groupHepatic resectionLiver metastasesUnresectable groupMedian disease-free survivalComparable long-term survivalOutcomes of patientsDisease-free survivalKaplan-Meier methodLog-rank testLong-term survivalDiagnostic imaging studiesFavorable morbidityCRLM patientsPostoperative mortalityUnresectable diseaseMajor complicationsTumor numberResultsA totalSurgical oncologistsOutcome data
2010
Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors
Ellis M, Cassera M, Vetto J, Orloff S, Hansen P, Billingsley K. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. Hepato Pancreato Biliary 2010, 13: 59-63. PMID: 21159105, PMCID: PMC3019543, DOI: 10.1111/j.1477-2574.2010.00242.x.Peer-Reviewed Original ResearchConceptsOverall survival rateIntrahepatic cholangiocarcinomaR0 resectionSurgical treatmentR1/R2 resectionResectable intrahepatic cholangiocarcinomaPostoperative liver failureMainstay of treatmentOptimal patient selectionPostoperative complication rateKaplan-Meier methodCox hazard modelPreoperative hypoalbuminaemiaReplete patientsR2 resectionSurgical mortalityComplication rateSurgical resectionSurgical therapyWorse survivalClinicopathologic characteristicsLiver failureOperative detailsPrognostic factorsRecurrence outcomesAdjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards modelTechniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy
Lee D, Mitchell E, Jones M, Landry G, Liem T, Sheppard B, Billingsley K, Moneta G. Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy. Journal Of Vascular Surgery 2010, 51: 662-666. PMID: 20080375, DOI: 10.1016/j.jvs.2009.09.025.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaEdemaEndosonographyFemoral VeinGraft Occlusion, VascularHumansKaplan-Meier EstimateMesenteric VeinsMiddle AgedNeoplasm InvasivenessPancreatic NeoplasmsPancreaticoduodenectomyPortal VeinRegistriesReoperationSaphenous VeinTime FactorsTissue and Organ HarvestingTomography, X-Ray ComputedTreatment OutcomeUltrasonography, Doppler, DuplexVascular PatencyVascular Surgical ProceduresConceptsPV/SMV reconstructionLower extremity edemaLower extremity veinsPostoperative wound problemsLate mortalityExtremity edemaFemoral veinExtremity veinsSaphenous veinWound problemsPreoperative imagingPortal veinPV/SMV invasionSuperior mesenteric vein invasionPreoperative computed tomography (CT) imagingPV/SMVVein harvest siteLower extremity complicationsKaplan-Meier analysisGreat saphenous veinMinor operative proceduresEndoscopic ultrasound scanSuperior mesenteric vein reconstructionComputed tomography (CT) imagingPatent reconstruction
2009
Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era?
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era? Journal Of The American College Of Surgeons 2009, 208: 87-95. PMID: 19228509, DOI: 10.1016/j.jamcollsurg.2008.10.014.Peer-Reviewed Original ResearchConceptsPancreatic adenocarcinomaDiagnostic laparoscopyMetastatic diseaseSurgical explorationEndoscopic ultrasonographyDual-phase CT scanMultivariate logistic regression modelCornerstone of stagingPreoperative weight lossMedical record reviewSubset of patientsPopulation-based studyPancreatic cancer patientsState Cancer RegistrySound clinical approachCurrent imaging modalitiesCombination of CTCurrent staging techniquesLogistic regression modelsCurative intentPotential resectabilityResectable patientsLaparoscopic stagingPreoperative evaluationPrimary outcome
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimensDiagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era?
Enestvedt C, Mayo S, Diggs B, Mori M, Austin D, Shipley D, Sheppard B, Billingsley K. Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era? Journal Of Gastrointestinal Surgery 2008, 12: 1177-1184. PMID: 18470572, DOI: 10.1007/s11605-008-0514-y.Peer-Reviewed Original ResearchConceptsDiagnostic laparoscopyPancreatic cancerPancreatic adenocarcinomaUtilization of laparoscopyResectable pancreatic cancerResectable pancreatic adenocarcinomaPancreatic cancer databaseUse of laparoscopyState Cancer RegistryMedical record dataBiliary bypassPreoperative laparoscopyResectable patientsUnderwent laparoscopyUnresectable diseaseLaparoscopic explorationPeritoneal metastasisCancer RegistryStaging modalitiesCancer DatabaseAverage hospitalLaparoscopyMedicare dataPhysician chargesPatients